Lilly 1Q Revenues: $4.6 billion (-1%) 1Q Earnings: $529.5 million (-27%) Comments: Revenue in the U.S. increased 6% to $2.2 billion, driven by increased volumes for Cyramza (sales of $67.5 million), and the inclusion of revenue from Novartis Animal Health ($749.8 million, up 42%). Revenue outside the U.S. decreased 6% to $2.4 billion due to unfavorable impact of foreign exchange. Lingering effects of U.S. patent expirations for Cymbalta (-40% to $287 million) and Evista (-55% to $66.8 million...